Clinical Efficacy of Human Papillomavirus DNA Detection in Urine from Patients with Various Cervical Lesions by Song, Eun-Seop et al.
INTRODUCTION
Human papillomaviruses (HPVs) are naturally occurring
DNA tumor viruses which induce epithelial cell prolifera-
tion during the course of a productive infection, and epidemi-
ologic and laboratory data have clearly established that infec-
tion with specific types of human papillomavirus (HPV) app-
eared to be an essential step in the development of invasive
cervical cancer and its precursor lesion, cervical intraepithe-
lial neoplasia (CIN). HPV DNA can be identified in more
than 90% of invasive cervical carcinomas (1, 2), and women
who are HPV DNA positive but lack cervical lesions are
still at greatly increased risk for developing and progression
of CIN (3-5). To date, more than 96 HPV types have been
identified, of which approximately 30-40 types have been
found in female genital tract infections (6, 7).
The efficacy of the Pap smear for the screening method of
cervical cancer has been criticized due to substantial false neg-
ative rates and low participation rates. Approximately 10%
of women in the U.S.A. have never had a Pap smear and
approximately 30% of women do not have this examination
on a regular basis (8, 9) and the participation rate is even worse
in Australia (10). According to the recent nationwide survey
of Korean Ministry of Health and Welfare, just 58.5% of the
Korean women over 30 yr old had Pap Smear during last two
years (11). This rate is far lower than that of Western coun-
tries including the U.S.A. where 84.4% of the women over
18 yr had a Pap smear during last 3 yr (12). A Pap smear
requires a pelvic examination, which is invasive and uncom-
fortable for the patient as well as time-consuming for the
health care provider (13). In fact, 8.2% of Korean women in
their 4th decade chose fear and discomfort of the pelvic exam-
ination as the first reason for not having a Pap smear (11).
HPV DNA test is now accepted as a useful adjunctive
method that increases the sensitivity of the conventional cer-
vical cytology. Since most of HPV DNA tests use cervical
swab samples obtained by cytobrush as a DNA source, pati-
ents must overcome the discomfort and the emotional stress
of the colposcopic examination. Therefore, a reliable screening
method which is noninvasive and comfortable would increase
the participation rate. Perhaps the use of urine sample for the
detection of HPV could provide a preliminary screening for
a cervical cancer and thus circumvent the need for an annual
Pap smear for women who are negative for HPV DNA. Alter-
natively, detection of HPV DNA in urine can function as a
secondary screening technique for cervical cancer in triage for
women with atypical squamous cells of undetermined signifi-
cance (ASC-US). It has been previously reported that women
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Clinical Efficacy of Human Papillomavirus DNA Detection in Urine
from Patients with Various Cervical Lesions
A considerable number of adult Korean women avoid a Pap smear due to fear and
discomfort of the pelvic examination. A reliable but noninvasive and comfortable
screening method would considerably increase the participation rate. To evaluate
the clinical efficacy of urine-based human papillomavirus (HPV) detection by oligonu-
cleotide microarray, the results of HPV test from matched cervical swab specimens
were compared. HPV DNA was detected in 70 of 100 cervical samples. HPV 16
was the most prevalent type (38/70), followed by types 18, 58, 52, 33, 35, 31, and
51. HPV DNA was identified in 47 of 90 urine samples. HPV 16 was the most preva-
lent type (30/45), followed by types 18, 52, 35, 51, 58, 33, and 56. The HPV detec-
tion rates of the cervical swabs increased in accordance with the severity of the cyto-
logic and histologic diagnosis. The type specific agreement of HPV DNA tests bet-
ween cervical swabs and urine was good in HPV 16 (kappa index=0.64 [95% CI:
0.50-0.79]), 18, 52, and 58 and fair in HPV 33 and 35. We propose that a urine HPV
test is a valuable adjunctive method for a conventional Pap smear and can be used
in population screening for cervical cancer in countries where it is difficult to obtain
colposcopic specimens for cultural or religious reasons. 
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with cytological abnormalities are likely to have detectable
HPV DNA in urine as in cervical swab samples (14-16). There
has been only one preliminary report which evauated the effi-
cacy of urine HPV dectection in Korea (17).
We have previously reported that HPV detection and typ-
ing by HPV oligonucleotide microarray is a highly compa-
rable method to the previously used PCR-RFLP method (18).
We performed the present study to evaluate the clinical effi-
cacy of the urine-based HPV DNA detection by HPV oli-
gonucleotide microarray by comparing the results from ma-
tched cervical swab specimens. 
MATERIALS AND METHODS
The samples were collected consecutively from 181 Kore-
an women who visited the Department of Obstetrics and
Gynecology, Inha University Hospital, Incheon, Korea from
January to December 2003. Among those, 100 patients who
had adequately analysed cervical swabs for HPV DNA (beta-
globin positive) and a biopsy proven histological diagnosis
were selected for this study. Twenty three chronic cervicitis
patients, 48 patients with CIN, and 29 patients with inva-
sive cervical carcinomas, including 3 adenocarcinomas, were
analysed. 
Cell collection from patients
The cervical swab samples were collected by scraping the
uterine cervical canal with a small cytobrush after a Pap smear,
and the brush was put into a 15 mL centrifuge tube contain-
ing 7 mL of phosphate buffered saline. Urine samples were
collected two weeks after the cervical scraping was performed.
After cleaning the external genital area twice with alcohol
swab, the first voided 30 to 50 mL of urine was collected.
Specimens were collected as part of an informed consent pro-
tocol approved by the clinical studies committee of Inha Uni-
versity Hospital. 
DNA extraction from cervical swabs and urine samples
DNA was extracted using Wizard genomic DNA purifi-
cation kit (Promega, Madison, WI, U.S.A.). After vortexing
the 15 mL centrifuge tube to dissociate cells from a cyto-
brush and centrifugation at 1,200 rpm and 4℃ for 3 min,
DNA was isolated from cells by detergent lysis buffer and
protease digestion. RNA was removed by digestion with
ribonuclease and DNA was concentrated by ethanol precip-
itation. A 15 mL urine sample was centrifuged at 2,000 rpm
and 4℃for 5-10 min. After discarding the supernatant, DNA
was isolated as above. 
HPV detection and typing by oligonucleotide microarray
(HPV DNA Chip) 
HPV detection and genotyping was performed using an
HPV DNA Chip, a PCR-based DNA microarray system
(Biomedlab Co., Seoul, Korea). The HPV DNA Chip con-
tains 22 type specific probes; 15 high-risk groups (16/18/
31/33/35/39/45/51/52/56/58/59/66/68/69) and 7 low-risk
groups (6/11/34/40/42/43/44). The samples were prepared
according to the manufacturer’s instructions. The target HPV
DNA was amplified by PCR using primers (HPV and beta-
globin) supplied by the manufacturers. Amplified DNA was
labeled by Cy5-dUTP (NEN
�Life Science Products, Inc.,
Boston, MA, U.S.A.). The PCR product was mixed with a
hybridization solution made up of 6× SSPE (saline-sodium
phosphate-EDTA buffer, Sigma, St. Louis, MO, U.S.A.) and
0.2% SDS, and then hybridized on to the chip at 40℃ for 2
hr and washed with 3×SSPE and 1×SSPE for 2 min each.
Hybridized HPV DNA was visualized using a DNA Chip
Scanner (GSI Lumonics
�, Scanarray lite, Ottawa, Canada).
An image of a HPV oligonucleotide microarray is illustrat-
ed in Fig. 1.
Fig. 1. Patterns of HPV typing by HPV oligonucleotide microarray. Each slide contains a pair of oligonucleotide probes of the 22 HPV geno-
types. Image from a single HPV 16 infection (A), single HPV 18 infection (B), double HPV 16, 33 infection (C), and triple HPV 44, 59, 68
infection (D). A probe for beta-globin (BG) was used as an internal control.
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Statistical analysis
Ninety cases showing positive beta-globin bands in both
cervical and urine samples after PCR were analysed for the
agreement study. The rate of concordance for HPV detection
is a measure of whether both cervical and urine samples con-
tained any HPV type or whether no HPV was present in the
paired samples. The agreement of the result between HPV
detection in cervical swab and urine was evaluated using kappa
index which was defined by a chance corrected proportional
agreement rate. Kappa was meant to be adopted to improve
the simpler measure, a percent of agreement, because it dis-
counts the proportion of agreement which is expected by
chance alone (Pe). Instead of the total proportion of observa-
tions on which there is agreement (Po) being compared as a
ratio with its maximum value (100 percent), the attributable
proportion (Po-Pe), the fraction of observations for which agree-
ment can be attributed to the reproducibility of the obser-
vations rather than to mere chance, is compared as a ratio
with its maximum possible value (1-Pe). Thus,
K= Po-Pe
1-Pe
It has maximum of 1.00 when agreement is perfect, a value
of zero indicates no agreement better than chance, and nega-
tive values show worse than chance agreement, which is un-
likely (19).
RESULTS
Patient characteristics 
The patients’ age ranged from 26 to 77 yr, with a mean of
45.2 yr. Mean±SD of parity was 2.0±0.89. Ninty five
patients have been married for 16 to 43 yr with a mean of
23.9 yr.
HPV prevalence in cervical swabs and urine samples
DNA was present in all samples extracted from cervical
cytobrush swabs and in 90 (90.0%) of 100 samples extracted
from urine. HPV DNA was detected in 70 (70.0%) of 100
cervical samples; 4 (17.4%) of 23 chronic cervicitis, 40 (83.3
%) of 48 CIN, and 26 (89.7%) of 29 carcinoma samples and
were all high risk HPVs except for one triple infection. HPV
16 was the most prevalent type (38 of 70 patients, 54.3%),
followed by type 18 (n=5, 7.1%), type 58 (n=5, 7.1%), type
52 (n=4, 5.8%), types 33 (n=3, 4.3%), type 35 (n=3, 4.3%),
type 31 (n=2, 2.9%), and type 51 (n=2, 2.9%). Multiple
HPV infection was identified in 8 (11.4%) of 70 HPV-pos-
itive patients. HPV DNA was identified in 47 (52.2%) of
90 urine samples; 3 (13.0%) of 23 chronic cervicitis, 27 (62.8
%) of 43 CIN, and 17 (70.8%) of 24 carcinoma patients and
were all high-risk HPVs except for one triple infection. HPV
16 was the most prevalent type (30 of 45 patients; 63.8%),
followed by type 18 (n=3, 6.4%), type 52 (n=3, 6.4%), type
35 (n=2, 4.3%), type 51 (n=2, 4.3%), type 58 (n=2, 4.3%),
type 33 (n=1, 2.1%), type 56 (n=1, 2.1%). Multiple infec-
tion was identified in 3 (6.4%) of 47 HPV-positive patients
(Table 1). The cytologic diagnosis of 100 cases was normal
in 24 cases, ASC-US in 2 cases, atypical squamous cells can-
not exclude HSIL in 4 cases, SIL in 44 cases (low-grade squa-
mous intraepithelial lesion in 2 cases and high-grade squamous
intraepithelial lesion in 42 cases), and carcinoma in 26 cases
(squamous cell carcinoma [SCC] in 25 cases and adenocarci-
noma in 1 case). Among 70 cervical HPV positive cases, 5
HPV
Chronic cervicitis (%)
Cervix swab Urine
CIN (%)
Cervix swab Urine
Carcinoma (%)
Cervix swab Urine
Total (%)
Cervix swab Urine
HPV positive cases 4 (17.4) 3 (13.0) 40 (83.3) 27 (62.8) 26 (89.7) 17 (70.8) 70 (70.0) 47 (52.2)
Type 16 3 (75.0) 2 (66.7) 17 (42.5) 16 (59.3) 18 (69.2) 12 (70.5) 38 (54.3) 30 (63.8)
Type 18 3 (7.5) 2 (7.4) 2 (7.7) 1 (5.9) 5 (7.1) 3 (6.4)
Type 31 1 (2.5) 1 (3.8) 2 (2.9)
Type 33 1 (2.5) 2 (7.7) 1 (5.9) 3 (4.3) 1 (2.1)
Type 35 3 (7.5) 1 (3.7) 1 (5.9) 3 (4.3) 2 (4.3)
Type 51 1 (25.0) 1 (33.3) 1 (3.8) 1 (5.9) 2 (2.9) 2 (4.3)
Type 52 4 (10.0) 3 (11.1) 4 (5.8) 3 (6.4)
Type 56 1 (3.7) 1 (2.1)
Type 58 5 (12.5) 2 (7.4) 5 (7.1) 2 (4.3)
Multiple positive 6 (15.0) 2 (7.4) 2 (7.7) 1 (5.9) 8 (11.4) 3 (6.4)
16, 33
16, 52 (2) 16, 52
16, 56 16, 56 44, 59, 68 44, 59, 68
16, 58
33, 66
51, 58
Total 23 23 48 43 29 24 100 90
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cases (20.8%) of 24 normal group were HPV positive, 1 of
2 ASC-US cases, 4 of 4 ASC-H cases, 36 of 44 SIL cases and
24 of 26 carcinoma cases. Histologically, 2 ASC-US cases
exhibited a chronic cervicitis and a CIN I. Four ASC-H cases
were CIN III. The HPV DNA detection rate of the cervical
swab samples increased in accordance with the severity of the
cytologic and histologic diagnosis, and was higher than the
rate of urine samples in both CIN and carcinoma patients
(Table 1, 2). The concordance rate for HPV detection between
cervical swabs and urine was 69.3%. The type specific agree-
ment of the HPV DNA test between cervical swabs and urine
was good in HPV 16, 18, 52, and 58 and fair in HPV 33 and
35 (Table 3).
DISCUSSION
Cervical cancer is the fifth most common cancer in Kore-
an women (20). However, a substantial proportion of Kore-
an women do not visit a gynecology clinic unless they expe-
rience a specific problem. This phenomenon may also be
present in most of Asian and Arabic countries, where women
are reluctant to have pelvic examinations for cultural or reli-
gious reasons. There is an increasing population of unmar-
ried women who had sexual experiences in these countries.
Those women would be more reluctant to visit gynecology
clinic to get a routine Pap smear. In fact, more than 40% of
Korean women over age 30 yr do not have a Pap smear on a
regular base (11). Strategies for preventing cervical cancer in
countries similar to Korea must overcome the barriers of poor
rates of participation in screening programs and an inade-
quate medical infrastructure. Therefore, a screening of cer-
vical cancer bypassing an invasive colposcopic examination
would provide a greatly increased chance of participation in
these countries compared to the Western countries.
Even though HPV DNA test is now accepted as a useful
adjunctive method to the conventional cervical cytology, HPV
DNA test using cervical swab samples still requires colpo-
scopic examination. Urine HPV test would identify a major-
ity of women with CIN even though substantial proportion
of the women without CIN would also be positive for high
risk HPVs. On the other hand, a negative urine HPV assay
for high risk HPVs would strongly indicate normal cervical
cytology (15). HPV assays of urine samples have an advan-
tage in sample collection. The sample collection is done by
a method that is noninvasive and is readily accepted in clin-
ical practice. Several studies have explored the use of self-col-
lected material for HPV DNA testing with various methods
(14-17, 21). The other advantage is a simultaneous detection
of other common sexually transmitted diseases that affect
the cervix, such as Chlamydia trachomatis and Neisseria gonor-
rhoeae infections (22). These reports support our proposition
that a urine HPV test may be used as an adjunct to conven-
tional Pap smear or replace the Pap smear for the mass pop-
ulation screening of Korean cervical cancer in the future.
In the present study, the overall detection rate of HPV in
adequate urine sample was 52.2% and increased to 62.8%
Cytologic 
diagnosis
No. HPV positive/
total (%)
Chronic cervicitis
No. HPVpositive/
total (%)
CIN I
No. HPV positive/
total (%)
CIN II+III
No. HPV positive/
total (%)
Carcinoma
No. HPV positive/
total (%)
Histologic diagnosis
Normal 5/24 (20.8) 3/22 (13.6) 2/2 (100.0)
ASC-US 1/2 (50.0) 1/1 (100.0) 0/1 (0.0)
ASC-H 4/4 (100.0) 4/4 (100.0)
SIL 36/44 (81.8)
LSIL 0/2 (0.0) 0/2 (0.0)
HSIL 36/42 (85.7) 1/1 (100.0) 30/35 (85.7) 5/6 (83.3)
Carcinoma 24/26 (92.3)
SCC 23/25 (92.0) 3/3 (100.0) 20/22 (90.9)
AC 1/1 (100.0) 1/1 (100.0)
Total 70/100 (70.0) 4/23 (17.4) 1/4 (25.0) 39/44 (88.6) 26/29 (89.7)
Table 2. The comparison of cytologic and histologic diagnosis and HPVs distribution
Presence of HPV DNA 
in cervical swabs/urine
+/+ +/-- /+ -/-
HPV types
Kappa
index
Type 16 29 15 2 44 0.64
Type 18 2 3 1 84 0.58
Type 33 1 3 0 86 0.39
Type 35 1 2 1 86 0.39
Type 52 3 4 0 83 0.58
Type 58 3 3 0 84 0.65
Table 3. The type specific agreement of HPV test between cer-
vical swabs and urines by oligonucleotide microarray
ASC-US, atypical squamous cells of undetermined significance; ASC-H, atypical squamous cells cannot exclude HSIL; SIL. squamous intraepithelial
lesion; LSIL, low-grade squamous intraepithelial lesion; HSIL, high grade squamous intraepithelial lesion; SCC, squamous cell carcinoma; AC, ade-
nocarcinoma.in CIN and 70.8% in carcinoma. This result was similar to
that of Stanczuk et al. (23) showing 72% urine HPV DNA
positivity in cervical cancer patients and higher than that of
Brinkman et al. (24) showing overall 48% urine HPV DNA
detection rate. The findings of higher detection rate in the
cervix are consistent with the concept that HPV in urine lar-
gely represents passive carryover of HPV-infected cells from
the genital tract. The concordance rate of 69.3% for HPV
detection in cervical swabs and urine in the present study was
almost same as that of Brinkman et al. (24). The type spe-
cific agreement of the result between HPV test in cervical
swabs and urine was rather in a wide range. HPV 16 which
has a relatively large sample size showed a good agreement
(kappa index=0.64 [95% CI:0.50-0.79]). However, the posi-
tive rate for other types are too low to assess the confidence
interval of kappa index (25).
The major drawback of urine samples in our study was that
it was a poor source of DNA in 10 of 100 cases (10.0%). This
was slightly better than that of Stanczuk et al. (23) who were
able to detect DNA in 81% of the urine samples. The small
amount of HPV DNA in urine samples makes urine HPV
testing difficult and sometimes unsuccessful. Others have
even reported inhibitory effects of urine on PCR (16). Since
the main source of DNA and HPV in urine was attributed to
the contamination by desquamated cervical cells, the amount
of HPV DNA in the urine may thus be related to the quan-
tity of the epithelial cells as well as viral load. The result of
present study showing higher HPV positivity of urine sam-
ples in carcinoma patients also supports this idea. The yield
of HPV DNA obtained from urine could be improved by
collecting larger sample volumes such as 24 hr urine or full
first voided urine. Serial tests rather than a single test aug-
ment the sensitivity of an assay. Given the simplicity of ob-
taining urine samples, we could detect transient, prolonged,
and persistent HPV infection which carries a risk of malig-
nant transformation. Even though the detection rate of urine
samples and the agreement rate of HPV test between cervi-
cal swab and urine was not highly satisfactory at this point,
this test still have an advantage of detecting cervical cancer
or its precursor lesion in population who will not be exposed
to a Pap smear. It is also promising that we could improve
the yield of HPV DNA of urine and the sensitivity of the
HPV detection.
A global effort to improve the prevention of cervical can-
cer by a Pap smear is still worthwhile especially in develop-
ing countries. However, given the low accuracy rate (26) and
the low participation rate (8-11) of the conventional Pap smear
based cancer screening, we would improve the efficacy of cer-
vical cancer screening in Korea by applying a HPV test of
self-collected urine specimen as an adjunct to the conventional
Pap smear, or even a tool for cervical cancer screening.
Urine testing as a substitute for cytologic evaluation appears
to have little use when cytologic testing is readily available
and acceptable. However, it may be a valuable adjunctive
method for a conventional Pap smear or can be used in pop-
ulation screening for cervical cancer where obtaining genital
specimens is difficult for cultural or religious reasons. Fur-
ther research with a larger sample size, and an improved tech-
nology for sample collection, DNA retrieval, and the detec-
tion system is needed.
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